

Remarks

In the Official Communication dated 23 June 2008, restriction to one of the following independent and distinct groups of invention was required:

Group I	Claims 1-6, 8-11, and 19, in part,	drawn to formula (I) wherein the rings A represents a six member ring wherein W is N; and X, Y, and Z, are C;
Group II	Claims 1-6, 8-11, and 19 in part	drawn to formula (I) wherein the rings A represents a six member ring wherein Z is N; and X, Y, and W, are C;
Group III	Claims 1-5, 7-11, and 19 in part	drawn to drawn to formula (I) wherein the rings A represents a five member ring wherein W is S and , X, Y, and Z, are C;
Group IV	Claims 1-11, and 19 in part	drawn to drawn to formula (I) wherein the rings A represents a five or six member ring other than the above groups I-III;
Group V	Claims 13-14, 17, 21, and 23-27 in part,	drawn to a method of treating dyslipidemia or atherosclerosis or increasing plasma HDL-cholesterol using a compound of formula (I) wherein the rings A represents a six member ring wherein W is N; and X, Y, and Z, are C;
Group VI	Claims 13-14, 17, 21, and 23-27 in part,	drawn to a method of treating dyslipidemia or atherosclerosis or increasing plasma HDL-cholesterol using a compound of formula (I) wherein the rings A represents a six member ring wherein Z is N; and X, Y, and W are C;
Group VII	Claims 13-14, 17, 21, and 23-27 in part,	drawn to a method of treating dyslipidemia or atherosclerosis or increasing plasma HDL-cholesterol using a compound of formula (I) wherein the rings A represents a six member ring wherein W is S and X, Y, and Z, are C;
Group VIII	Claims 13-14, 17, 21, and 23-27 in part,	drawn to a method of treating dyslipidemia or atherosclerosis or increasing plasma HDL-cholesterol using a compound of formula (I) wherein the rings A represents a five or six member ring other than the above groups I-III.

In addition, upon election of any of Groups I-VIII a further selection of a single disclosed species for initial examination was required.

In response the Applicants elect for substantive examination Group I, claims 1-6, 8-11, and 19 without traverse.

Applicants further select for initial examination the species of Example 11.

The undersigned would like to preserve the opportunity to rejoin one or more method/process claims upon allowance of a suitable compound claim.

The claims have been amended to conform to the restriction requirement. It is believed

that the amendments to not add new matter. Support for the amendments can be found in application, particularly the claims and examples as filed.

Respectfully submitted,

/James B. Myers/
James B. Myers
Attorney for Applicants
Registration No. 42,021
Phone: 317-276-0755

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
August 7, 2008_____